Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Receivables (2017 - 2026)

Organogenesis Holdings has reported Receivables over the past 9 years, most recently at $217.5 million for Q4 2025.

  • For Q4 2025, Receivables rose 82.06% year-over-year to $217.5 million; the TTM value through Dec 2025 reached $217.5 million, up 82.06%, while the annual FY2025 figure was $217.5 million, 82.06% up from the prior year.
  • Receivables for Q4 2025 was $217.5 million at Organogenesis Holdings, up from $182.2 million in the prior quarter.
  • Over five years, Receivables peaked at $217.5 million in Q4 2025 and troughed at $72.0 million in Q1 2021.
  • A 5-year average of $105.1 million and a median of $95.3 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: skyrocketed 120.03% in 2021 and later fell 8.33% in 2023.
  • Year by year, Receivables stood at $82.5 million in 2021, then grew by 8.48% to $89.4 million in 2022, then fell by 8.33% to $82.0 million in 2023, then surged by 45.66% to $119.4 million in 2024, then surged by 82.06% to $217.5 million in 2025.
  • Business Quant data shows Receivables for ORGO at $217.5 million in Q4 2025, $182.2 million in Q3 2025, and $120.4 million in Q2 2025.